Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Isolated limb perfusion in regional melanoma.

Eva M Noorda1, Bart C Vrouenraets, Omgo E Nieweg

  • 1Department of Surgery, Slotervaart Hospital, Louwesweg 6, Amsterdam 100 BK, the Netherlands. cheno@slz.nl

Surgical Oncology Clinics of North America
|April 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utility of recurrence-based surrogate endpoints for survival in adjuvant cancer trials: evidence from melanoma.

Journal of the National Cancer Institute·2026
Same author

Timing of Definitive Surgical Management of Primary Cutaneous Melanoma: Association With Survival.

ANZ journal of surgery·2026
Same author

Nodal radioactivity after lymphoscintigraphy as a guide to sentinel node-positivity in melanoma patients.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

ASO Visual Abstract: Cartilage Resection in the Surgical Management of Ear Melanoma.

Annals of surgical oncology·2025
Same author

Cartilage Resection in the Surgical Management of Ear Melanoma.

Annals of surgical oncology·2025
Same author

Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma.

JAMA dermatology·2025
Same journal

Small Incisions, Big Impact-Robotic Surgery Is Revolutionizing Cancer Care.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Cancer.

Surgical oncology clinics of North America·2026
Same journal

TeleSurgery: The Present and the Future for Minimally Invasive and Robotic Surgery.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Rectal Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive/Robotic Surgery for Colon Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery in Liver Transplantation.

Surgical oncology clinics of North America·2026
See all related articles

Adjuvant perfusion for primary melanoma is not recommended due to limited effects. However, it may help control recurring locoregional melanoma and is indicated for unresectable limb melanoma.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Treatments

Background:

  • Adjuvant perfusion is a treatment modality for melanoma.
  • Its efficacy for primary melanoma is limited.
  • It shows potential for managing recurrent and unresectable melanoma.

Purpose of the Study:

  • To evaluate the effectiveness of adjuvant perfusion in melanoma treatment.
  • To determine the role of perfusion in managing locoregional and unresectable melanoma.
  • To assess the feasibility and outcomes of repeat perfusion treatments.

Main Methods:

  • Review of clinical data on patients undergoing perfusion for melanoma.
  • Analysis of recurrence rates and lesion burden in patients with locoregional melanoma.
  • Assessment of response rates in unresectable limb melanoma, particularly with TNF-a use.

Related Experiment Videos

  • Evaluation of repeat perfusion feasibility and outcomes.
  • Comparison of quality of life in survivors with the general population.

    • Main Results:

    • Adjuvant perfusion for primary melanoma is not recommended due to limited efficacy.
    • Perfusion may offer locoregional disease control for recurrent melanoma by reducing recurrences and lesions.
    • Unresectable limb melanoma is a primary indication for perfusion.
    • Higher response rates are observed with TNF-a in patients with high tumor burden.
    • Repeat perfusion is feasible with response rates similar to initial treatments.
    • Older age is not a contraindication for perfusion.
    • Long-term quality of life for survivors is comparable to the general population.

    Conclusions:

    • Adjuvant perfusion is not advised for primary melanoma excision.
    • Perfusion can be valuable for locoregional disease control in recurrent melanoma.
    • Further randomized studies are required to confirm its role in resectable recurrences.
    • Perfusion is indicated for unresectable limb melanoma, with better outcomes using TNF-a in high tumor load cases.
    • Repeat perfusions are safe and effective, and age is not a limiting factor.